These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6138683)

  • 1. False negative results with latex-based test for fibrinogen degradation products.
    Copplestone A; Francis D; Chisholm M
    Lancet; 1983 Nov; 2(8359):1444. PubMed ID: 6138683
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent progress on analysis of blood coagulation factors and fibrinolytic agents; FDP D dimer analysis using NANOPIA FDP].
    Matsumoto T; Sakai Y; Maeda M; Takei F
    Rinsho Byori; 1989 Apr; Spec No 81():183-8. PubMed ID: 2754806
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical evaluation of a test for plasma fibrin/fibrinogen degradation products (FDP) based on monoclonal anti-FDP antibody technology: an application for the scoring system of the disseminated intravascular coagulation (DIC) diagnostic criteria].
    Ito K; Wada H; Abe Y; Tomatsu H; Nishioka J; Nobori T
    Rinsho Byori; 2003 Apr; 51(4):295-9. PubMed ID: 12747249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False-negative test for fibrinogen--fibrin degradation products.
    Kickler T; Bell WR
    Am J Clin Pathol; 1977 Jul; 68(1):78-80. PubMed ID: 868807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of whole blood D-dimer test to plasma D-dimer test for diagnosis of disseminated intravascular coagulation.
    Gupta PK; Gupta M; Chatterjee T; Saxena R
    Indian J Exp Biol; 2005 Apr; 43(4):382-4. PubMed ID: 15875726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point-of-care testing in snakebite: an envenomed case with false negative coagulation studies.
    Cubitt M; Armstrong J; McCoubrie D; White J; Williams V; Isbister GK
    Emerg Med Australas; 2013 Aug; 25(4):372-3. PubMed ID: 23911031
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fibrin/fibrinogen degradation products (FDP)].
    Kuroso K; Fujimaki M
    Nihon Rinsho; 1989 Dec; 48 Suppl():892-5. PubMed ID: 2622025
    [No Abstract]   [Full Text] [Related]  

  • 8. A clinical evaluation of Thrombo-Wellcotest as a screening test for D.I.C.
    Song KS; Ahn YM; Kim HS; Lee SY
    Yonsei Med J; 1980; 21(1):58-61. PubMed ID: 7269637
    [No Abstract]   [Full Text] [Related]  

  • 9. [FDP-E--quantitative analysis by LPIA (latex photometric immunoassay) method].
    Furusaki F; Sudo T; Tsutsui S
    Rinsho Byori; 1989 Apr; Spec No 81():168-75. PubMed ID: 2754804
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of a latex test for determining the fibrinogen/fibrin D-dimer (XDP)].
    Barsotti A; Savarino A
    Quad Sclavo Diagn; 1987 Dec; 23(4):421-4. PubMed ID: 3508302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical comparison of AxSYM, HemosIL DD HS and Innovance D-dimer immunoassays with the Vidas D-dimer.
    Salvagno GL; Lippi G; Manzato F; Giavarina D; Montagnana M; Poli G; Guidi GC
    Int J Lab Hematol; 2009 Aug; 31(4):475-7. PubMed ID: 18503567
    [No Abstract]   [Full Text] [Related]  

  • 12. A latex immunoassay of fibrin/fibrinogen degradation products in plasma using a monoclonal antibody.
    Mirshahi M; Soria J; Soria C; Perrot JY; Boucheix C
    Thromb Res; 1986 Dec; 44(6):715-28. PubMed ID: 3798417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cross-linked fibrin polymer and degradation products by plasmin (XDP)].
    Kawai Y
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():618-22. PubMed ID: 15658405
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of kits for the detection of fibrin(ogen) degradation products in dogs.
    Stokol T; Brooks M; Erb H; Mauldin GE
    J Vet Intern Med; 1999; 13(5):478-84. PubMed ID: 10499733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differential determination of fibrinogen degradation products in assessment of the stages of plasma consumption in patients with infection and liver cirrhosis].
    Raschka C; Róka L
    Leber Magen Darm; 1993 Jan; 23(1):31-4. PubMed ID: 8445974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quantitative analysis of crosslinked fibrin degradation products (XDP) in several diseases].
    Saito M; Asakura H; Ito K; Joukaji H; Uotani C; Kumabashiri I; Matsuda T
    Rinsho Ketsueki; 1988 Nov; 29(11):2042-7. PubMed ID: 3236412
    [No Abstract]   [Full Text] [Related]  

  • 17. [Assay of products of fibrin and fibrinogen degradation in disseminated intravascular coagulations. Evaluation of a new technique].
    Borschneck C; Dreyfus M; Bridey F; Edouard D; Meyer D
    Presse Med; 1995 May 6-13; 24(17):799-802. PubMed ID: 7630868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prototype quantitative assay for fibrinogen/fibrin degradation products. Clinical evaluation.
    Sigal SH; Cembrowski GS; Shattil SJ; Brown NM; Schifreen RS; Schwartz MW
    Arch Intern Med; 1987 Oct; 147(10):1790-3. PubMed ID: 3662708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of soluble fibrin monomer complexes in obstetric patients.
    Estellés A; Gilabert J; Aznar J
    Thromb Res; 1982 Nov; 28(4):575-9. PubMed ID: 7164037
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the soluble fibrin monomer complexes and other coagulation parameters in obstetric patients.
    Aznar J; Gilabert J; Estelles A; Fernandez MA; Villa P; Aznar JA
    Thromb Res; 1982 Sep; 27(6):691-701. PubMed ID: 7179210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.